The antidepressant-like effects of BU10119, a novel kappa opioid receptor antagonist, in the novelty-induced hypophagia task in mice

Sarah Bailey, Abdulrahman Mohammed I Almatroudi, Christopher Bailey, Stephen Husbands

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist, that was non-sedating and non-rewarding, with antidepressant like effects in the forced swim test and novelty-induced hypophagia task (Almatroudi et al. 2015. J. Psychopharmacol. In Press). We have developed a novel compound that combines the properties of buprenorphine/naltrexone combination into a single compound (Cueva et al. 2015. J Med Chem, In Press), thereby simplifying dosing and treatment regimens and avoiding abuse potential. Here, we present preliminary data that BU10119 is a functional kappa antagonist with antidepressant-like effects in mice. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine/naltrexone combination (1 mg/kg), fluoxetine (20 mg/kg) or BU10119 (1mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (4, 45) =9.15, P<0.001) but not consumption (F (4, 45) =1.25, P=0.3). BU10119 is a relatively short acting kappa-antagonist with little efficacy at the mu-opioid receptor. BU10119 has demonstrated activity in the novelty-induced hypophagia test that is consistent with the behavioural effects of fluoxetine and therefore has an antidepressant-like profile.
Original languageEnglish
Title of host publicationNeuroscience Meeting Planner
Subtitle of host publicationSociety for Neuroscience
Publication statusPublished - 2015
EventSociety for Neuroscience 2015 - Chicago, USA United States
Duration: 17 Oct 201521 Oct 2015

Conference

ConferenceSociety for Neuroscience 2015
CountryUSA United States
Period17/10/1521/10/15

Fingerprint

kappa Opioid Receptor
Narcotic Antagonists
Buprenorphine
Naltrexone
Antidepressive Agents
Fluoxetine
mu Opioid Receptor
Analysis of Variance
Milk
Pharmaceutical Preparations
F 4

Keywords

  • Depression

Cite this

The antidepressant-like effects of BU10119, a novel kappa opioid receptor antagonist, in the novelty-induced hypophagia task in mice. / Bailey, Sarah; Almatroudi, Abdulrahman Mohammed I; Bailey, Christopher; Husbands, Stephen.

Neuroscience Meeting Planner : Society for Neuroscience. 2015. 774.09.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bailey, S, Almatroudi, AMI, Bailey, C & Husbands, S 2015, The antidepressant-like effects of BU10119, a novel kappa opioid receptor antagonist, in the novelty-induced hypophagia task in mice. in Neuroscience Meeting Planner : Society for Neuroscience., 774.09, Society for Neuroscience 2015 , USA United States, 17/10/15.
@inproceedings{f8042ec5be9e454a9b9fed1ff333b388,
title = "The antidepressant-like effects of BU10119, a novel kappa opioid receptor antagonist, in the novelty-induced hypophagia task in mice",
abstract = "Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist, that was non-sedating and non-rewarding, with antidepressant like effects in the forced swim test and novelty-induced hypophagia task (Almatroudi et al. 2015. J. Psychopharmacol. In Press). We have developed a novel compound that combines the properties of buprenorphine/naltrexone combination into a single compound (Cueva et al. 2015. J Med Chem, In Press), thereby simplifying dosing and treatment regimens and avoiding abuse potential. Here, we present preliminary data that BU10119 is a functional kappa antagonist with antidepressant-like effects in mice. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine/naltrexone combination (1 mg/kg), fluoxetine (20 mg/kg) or BU10119 (1mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (4, 45) =9.15, P<0.001) but not consumption (F (4, 45) =1.25, P=0.3). BU10119 is a relatively short acting kappa-antagonist with little efficacy at the mu-opioid receptor. BU10119 has demonstrated activity in the novelty-induced hypophagia test that is consistent with the behavioural effects of fluoxetine and therefore has an antidepressant-like profile.",
keywords = "Depression",
author = "Sarah Bailey and Almatroudi, {Abdulrahman Mohammed I} and Christopher Bailey and Stephen Husbands",
year = "2015",
language = "English",
booktitle = "Neuroscience Meeting Planner",

}

TY - GEN

T1 - The antidepressant-like effects of BU10119, a novel kappa opioid receptor antagonist, in the novelty-induced hypophagia task in mice

AU - Bailey, Sarah

AU - Almatroudi, Abdulrahman Mohammed I

AU - Bailey, Christopher

AU - Husbands, Stephen

PY - 2015

Y1 - 2015

N2 - Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist, that was non-sedating and non-rewarding, with antidepressant like effects in the forced swim test and novelty-induced hypophagia task (Almatroudi et al. 2015. J. Psychopharmacol. In Press). We have developed a novel compound that combines the properties of buprenorphine/naltrexone combination into a single compound (Cueva et al. 2015. J Med Chem, In Press), thereby simplifying dosing and treatment regimens and avoiding abuse potential. Here, we present preliminary data that BU10119 is a functional kappa antagonist with antidepressant-like effects in mice. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine/naltrexone combination (1 mg/kg), fluoxetine (20 mg/kg) or BU10119 (1mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (4, 45) =9.15, P<0.001) but not consumption (F (4, 45) =1.25, P=0.3). BU10119 is a relatively short acting kappa-antagonist with little efficacy at the mu-opioid receptor. BU10119 has demonstrated activity in the novelty-induced hypophagia test that is consistent with the behavioural effects of fluoxetine and therefore has an antidepressant-like profile.

AB - Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist, that was non-sedating and non-rewarding, with antidepressant like effects in the forced swim test and novelty-induced hypophagia task (Almatroudi et al. 2015. J. Psychopharmacol. In Press). We have developed a novel compound that combines the properties of buprenorphine/naltrexone combination into a single compound (Cueva et al. 2015. J Med Chem, In Press), thereby simplifying dosing and treatment regimens and avoiding abuse potential. Here, we present preliminary data that BU10119 is a functional kappa antagonist with antidepressant-like effects in mice. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine/naltrexone combination (1 mg/kg), fluoxetine (20 mg/kg) or BU10119 (1mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (4, 45) =9.15, P<0.001) but not consumption (F (4, 45) =1.25, P=0.3). BU10119 is a relatively short acting kappa-antagonist with little efficacy at the mu-opioid receptor. BU10119 has demonstrated activity in the novelty-induced hypophagia test that is consistent with the behavioural effects of fluoxetine and therefore has an antidepressant-like profile.

KW - Depression

M3 - Conference contribution

BT - Neuroscience Meeting Planner

ER -